Improving Access to Medicines for Neglected Tropical Diseases in Developing Countries: Lessons from Three Emerging Economies by Holt, Francesca et al.
Viewpoints
Improving Access to Medicines for Neglected Tropical
Diseases in Developing Countries: Lessons from Three
Emerging Economies
Francesca Holt
1*, Stephen J. Gillam
2, Jeremiah M. Ngondi
2
1St John’s College, University of Cambridge, Cambridge, United Kingdom, 2Department of Public Health and Primary Care, University of Cambridge, Cambridge, United
Kingdom
Introduction
Neglected tropical diseases (NTDs) are
those largely ignored by medical science,
partly because they do not represent a
viable commercial market for private
pharmaceutical companies. These diseases
are endemic in developing countries and
have a significant impact at both personal
and national levels. Globally, NTDs affect
an estimated 2.7 billion people living on
less than US$2 per day [1] and potently
reinforce the poverty cycle [2]. At present,
the prevailing strategy for improving
access to medicines for these NTDs is
drug donation programmes, which, de-
spite providing some of the highest
economic returns of public health pro-
grammes at 15%–30% [2,3], have uncer-
tain sustainability. Countries in demo-
graphic and economic transition are
uniquely poised to be leaders in a shift
towards a more sustainable, affordable
means of providing access to medicines
for NTDs.
The Position of the Emerging
Economies
China, India, and Brazil are three of the
largest of more than 20 countries in
economic and demographic transition
commonly referred to as emerging econ-
omies [4]. Along with Russia, they are
referred to as the ‘‘BRIC’’ countries and
are predicted to overtake the G6 countries
(United States, Japan, United Kingdom,
Germany, France, and Italy) in terms of
gross domestic product (GDP) by 2040 [5].
Their pharmaceutical industries are con-
comitantly booming; the pharmaceutical
market in China is expected to drive
US$40 billion in growth through 2013,
whilst Brazil and India are each expected
to add US$5–15 billion to the pharma-
ceutical market [6].
However, in terms of disease burden
and health care, these countries continue
to suffer many of the problems found in
developing countries, including NTDs.
Brazil is estimated to be afflicted by six
of the NTDs, whilst China and India are
thought to harbour four [7]. Furthermore,
India, China, and the Americas account
for 59% of the world population without
access to essential medicines [8]. But these
countries are unique in that they have
managed to cultivate their own pharma-
ceutical industry with the capacity to
produce affordable drugs for NTDs for
use in domestic and international markets.
A review by Frew et al. identified 78
‘‘innovative home-grown, small to medi-
um-size health biotechnology companies
in the emerging economies in Brazil,
China, India and South Africa’’. These
‘‘had a collective pipeline of nearly 500
products for more than 100 indications’’.
Of the products for HIV, malaria, tuber-
culosis, and NTDs, two-fifths (40.5%) of
the products on the market and 62.9% of
the products in development were for
NTDs [9]. For example, Fungisome, a
liposomal amphotericin B used to treat
visceral leishmaniasis, was developed by
an Indian company, Lifecare Innovations.
Dermacerium, a topical agent used in the
treatment or prophylaxis of skin infections
in patients with leprosy, is produced by
Silvestre Labs, Brazil [9]. Clearly, these
countries recognise the worth of invest-
ment in developing medicinal tools to
combat NTDs and have the capacity to do
so.
Experiences of India and Brazil
So how are the emerging economies
working to improve access to medicines
for NTDs? Lower costs are helping to
stimulate the development of medicines in
these emerging economies. The cost of
research and development (R&D) and
manufacturing in India and China are
estimated to be one-eighth and one-fifth of
the costs incurred by Western companies,
respectively. This is attributed to lower
fixed asset costs (i.e., lower costs of
building manufacturing facilities), cheaper
labour, lower costs of regulation, efficient
manufacturing processes, a large suitable
population to be recruited quickly and
cheaply for clinical trials, and inexpensive
marketing [10].
In India, the pharmaceutical industry
grew through utilisation of low R&D costs
and its building of generic drug production
facilities. Later, when forced by the
Agreement on the Trade-Related Aspects
of Intellectual Property Rights (TRIPS), it
moved towards innovative drug produc-
tion. Brazil went through a similar process
of utilising low production costs and
expanding its generic drug industry. How-
ever, there was a key difference: the
manner in which it dealt with the
introduction of the TRIPS by the World
Trade Organization (WTO). Here, we see
how government technological and indus-
trial policies have proved extremely influ-
ential in stimulating R&D [11].
Under the TRIPS Agreement, members
of the WTO have to provide patent
protection for inventions, which includes
medicines and their methods of manufac-
ture. Patent protection has to last at least
20 years from the date the patent appli-
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ment permitted a transition period of 10
years in which developing countries could
adapt. During the transition, a ‘‘mailbox’’
for patent deposits was set up. This system
allowed patent deposits before the agree-
ment to be placed in the ‘‘mailbox’’ and
held there for the transition period before
a decision need be made. India made full
use of this transition period. The Indian
Patents Act of 1970, which granted patent
rights only to manufacturing processes,
prevailed throughout the transition, until
2005. This act allowed Indian pharma-
ceutical companies to perform reverse
engineering of branded drugs and sell
them as generic drugs. The mailbox
system also meant that Indian companies
were able to predict which drugs were
waiting for patent and adapt accordingly.
When it came to the end of the transition
period, patents were only granted in cases
where there was no local production.
Alongside policies to support development
of local pharmaceutical companies such as
high import tariffs, restriction of foreign
direct investment, and price control, the
way in which they adapted to the TRIPS
Agreement allowed greater development
of the national pharmaceutical industry
[11].
Brazil, however, became fully compliant
with the agreement after 2 years (by 1996).
Once the agreement was implemented,
Brazil began granting patents. Every
depositor who had obtained a patent in
another country could request one in
Brazil without assessment. This pipeline
mechanism also allowed a retroactive
examination of patent deposits from prod-
ucts that only became patentable after the
enactment of the new law [11].
The results of these different govern-
ment policy decisions are marked. During
the transition period, Brazil saw a decrease
in its national market, whereas India had
fostered a significant increase. Whilst
Brazil was in negative trade balance for
pharmaceutical and medicinal products,
India was in positive trade balance and
had achieved near self-sufficiency in most
drugs and pharmaceuticals [13]. The
multinational corporations with their
‘‘persistent hegemony’’ in the Brazilian
market benefited from the application of
TRIPS to Brazil, but the Brazilian com-
panies did not [14].
As described by Morel et al., Brazil is
trying to make up for lost ground with
their new legal and regulatory framework,
which includes the Law of Technological
Innovation [15], and their Biotechnology
Development Policy. These policy and
legal changes are helping to generate new
drugs to treat NTDs by bridging the gap
between basic research and drug develop-
ment. For example, the Brazil Department
for Science and Technology and Ministry
of Science and Technology together
invested US$10 million in 76 peer-re-
viewed projects as part of a pilot R&D
programme in 2007–2008 that aims to
tackle dengue fever, Chagas’ disease,
leprosy, malaria, tuberculosis, and leish-
maniasis. The programme builds on
existing international networks of research
and aims to strengthen capacity for
research on NTDs, particularly in regions
of Brazil where these diseases are endemic
[13]. Furthermore, much can be learned
about improving access to medicines from
the successes of the Brazilian efforts to
guarantee free antiretrovirals for patients
with HIV/AIDS. Whilst local production
of antiretroviral drugs was paramount,
where this was not possible the drugs were
imported as cheaply as could be negotiat-
ed. This was made possible by judicious
use of compulsory licensing as a bargain-
ing tool, and later by actual issue of a
compulsory license [16,17].
Lessons and Their Application
From observations of the experiences of
emerging economies such as India and
Brazil, it can be seen that developing a
competitive national pharmaceutical in-
dustry has the potential to ensure sustain-
able and affordable development of drugs
for NTDs. These observations also under-
score the importance of managing intel-
lectual property and laws that support
innovation.
Capacity for achieving comparable
improvement in access to medicines in
other emerging economies is as yet an
untapped resource. It has been suggested,
by Frew et al., that a ‘‘Global Health
Accelerator’’ is needed to scale up the
product development efforts of these
emerging-economy firms [9]. The accel-
erator would create a shift away from the
less sustainable business of product devel-
opment at high costs followed by charita-
ble donation, and towards affordable
innovation. The accelerator model would
utilise push and pull mechanisms to
incentivise drug development, as well as
support small firms in international busi-
ness issues such as understanding regula-
tory environments, assessing markets, po-
sitioning products, identifying distribution
channels, accessing financing, and identi-
fying international commercialisation
partners. It would also facilitate collabo-
rative endeavours including public–private
partnerships [9]. However, such ideas
must go beyond the emerging economies.
It is crucial that the lessons about stimu-
lating innovation are shared effectively
with the developing world.
There are early signs of efforts to scale
up nascent drug R&D in developing
nations. The first meeting of the new
African Network for Drugs and Diagnos-
tics Innovation (ANDI) was held in
October 2008. The goal of the ANDI is
to develop locally sustainable health R&D
coordinated through an African-based and
-led organisation [18,19]. Similarly, the
Initiative to Strengthen Health Research
Capacity in Africa (ISHRECA) ‘‘seeks to
promote the creation of self-sustaining
pools of excellence capable of initiating
and carrying out high quality health
research in Africa as well as translating
research products into policy and practice
through better integrated approaches of
capacity building at individual, institution-
al and system levels’’ [20].
Superimposed on these Africa-based
organisations, The South-South Initiative
works to promote collaboration between
disease-endemic countries across Africa,
Latin America, and Asia in the application
of scientific, technological, and methodo-
logical advances to infectious diseases of
poverty [21]. As exemplified by the
investment made by Cipla, a large Indian
pharmaceutical company, in the manufac-
ture of antiretrovirals by Uganda’s Quality
Chemicals Industries, such collaborations
are already helping tackle access to
medicines for HIV. In this case, the
viability of such collaboration was provid-
ed by advanced market commitments
made by the Ugandan government as well
as the promise of a market across the
whole of Eastern Africa [22]. The begin-
nings of similar collaborative initiatives for
NTDs can be seen. For example, a
research network linking Brazil with
Ghana, Nigeria, Angola, and Mozam-
bique has been set up so that research
and experience on NTDs can be shared
[23].
Conclusion
Currently, the dominant strategy for
ensuring access to medicines for NTDs is
drug donation from Western pharmaceu-
tical companies. But this dependence upon
profit-driven organisations is precarious.
Clearly, a more sustainable approach is
required. Unlike many developing coun-
www.plosntds.org 2 February 2012 | Volume 6 | Issue 2 | e1390tries, the emerging economies not only
have a large NTD burden, but they are
also beginning to show us a means of
improving access to medicines for NTDs
in a more sustainable fashion. They are
developing their own policies of innova-
tion, their own pharmaceutical industries,
and their own medical solutions to NTDs.
Their experiential knowledge is surely
invaluable and can help to guide develop-
ing countries towards sustainable strategies
to control NTDs.
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